Back

Akeso’s ivonescimab cuts lung-cancer death risk 27% versus Keytruda

Verifying
  • Akeso’s ivonescimab outperformed Keytruda in first-line non-small cell lung cancer treatment.
  • Ivonescimab recorded 30.8 months’ median survival versus Keytruda’s 22.6 months.
  • HARMONi-2 enrolled Chinese patients; Summit Therapeutics’ global HARMONi-7 results are expected as early as 2028.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Akeso’s ivonescimab cuts lung-cancer death risk 27% versus Keytruda - CoinPost Terminal